

Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
						AMG-Studien				
Mamma-Ca	x				NeoMONO EudraCT Number 2020-001651-40	An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer comparing a mono Atezolizumab window followed by a Atezolizumab-CTX therapy with Atezolizumab- CTX therapy (NeoMONO)				x
Mamma-Ca	x	x			ADAPTcycle EudraCT Number 2018-003749-40	Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk, HR+/HER2- early breast cancer (ADAPTcycle)	x			
Mamma-Ca			x		SASCIA EudraCT Number 2019-004100-35	Phase III postneoadjuvant study evaluating Sacituzumab Govitecan , an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA	x			x
Mamma-Ca				x	CBYL719H12301 EPIK-B3 EudraCT Number 2019-002637-11	EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess safety and efficacy of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation				x
Mamma-Ca				x	DESTINY-Breast12 EudraCT Number 2020-005048-46	An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer (DESTINY-Breast12)		x	x	
Mamma-Ca				x	SERENA-6 EudraCT Number 2021-000546-17	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study	x			
Mamma-Ca				x	Destiny Breast 07 EudraCT Number 2019-004531-22	A Phase Ib/II Multicenter, Open-label, Modular, Dose-finding and Dose expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)		x	x	
Mamma-Ca				x	Tropion-Breast 01 EudraCT Number 2020-005620-12	A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor Positive / HER2 Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy	x			



Mamma-Ca					Reko Hammor	Prospektive Kohortenstudie zur Erfassung der Lebensqualität, des chirurgischen Outcomes und perioperativer Komplikationen nach implantatbasierter Brustrekonstruktion				
	Primär	Metastasiert								
Ovar-Ca		x			AGO-OVAR 2.29 EutraCT Number 2017-000202-37	Atezolizumab in Kombination mit Bevacizumab und Che-motherapie versus Bevacizumab und Chemotherapie in rezidivierendem Ovarialkarzinom – eine randomisierte Phase III Studie				
Ovar-Ca					GRACE NOGGO ov50	Non-Interventional study protocol Registry of Rucaparib in Clinical Practice – An evaluation of clinical experience in Germany				
Ovar-Ca		x			FraStrROC	Development and prospective validation of a Frailty Score for chemotherapy associated side effects in Relapsed Ovarian Cancer				
Ovar-Ca		x			MIROVA AGO-OVAR 2.34 EudraCT Number 2018-004207-39	A randomized phase II trial of Mirvetuximab soravtansine (IMGN853) , in folate receptor alpha (FR α) high recurrent ovarian cancer eligible for platinum-based chemotherapy. (Protocol ID: AGO-OVAR 2.34).				

						Sonstige Studien					
Mamma- Ca und Schwangerschaft						GBG 29 BCP	Prospektive Registerstudie zur Diagnostik und Therapie des Mamma-karzinoms in der Schwangerschaft Pat. mit histologisch gesichertem Mammakarzinom und Schwangerschaft	x	x	x	x
Mamma-Ca				x		GBG79 BrainMet	Brain Metastases in Breast Cancer Network Germany (BMBC) Meeting a clinical need for the improvement of patient outcome	x	x	x	x
Mamma-Ca beim Mann						Register Magdeburg	Mammakarzinom des Mannes. Eine prospektive Registerstudie der Universitätsfrauenklinik Magdeburg in Zusammenarbeit mit den klinischen Krebsregistern zur Diagnostik und Therapie des Mammakarzinoms des Mannes	x	x	x	x



Schwesternschaft München
vom Bayerischen Roten Kreuz e.V.

ROTKREUZKLINIKUM
MÜNCHEN
FRAUENKLINIK

alle gyn. Tumorpatienten					Psychonkologische Studie von ONKOTRAKT	Epidemiologische Untersuchung zur Belastung von Krebspatienten (Verbesserung der Erkennung des psychoonkologischen Betreuungsbedarfs bei Krebskranken)				
Gyn-Sarkome					REGSA	Deutsche prospektive Registerstudie zur Erfassung der Behandlung von gynäkologischen Sarkomen in der klinischen Routine				